Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.

Date publication

janvier 2023

Journal

Therapeutic advances in medical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Dr ROYER Bernard

Tous les auteurs :
Callon S, Brugel M, Botsen D, Royer B, Slimano F, Feliu C, Gozalo C, Konecki C, Devie B, Carlier C, Daire V, Laurés N, Perrier M, Djerada Z, Bouché O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36643657

Résumé

Dihydropyrimidine dehydrogenase (DPD) deficiency screening is a pre-therapeutic standard to prevent severe fluoropyrimidine-related toxicity. Although several screening methods exist, the accuracy of their results remains debatable. In France, the uracilemia measurement is considered the standard in DPD deficiency screening. The objective of this study was to describe the hyperuracilemia (⩾16 ng/mL) rate and investigate the influence of hepatic and renal impairment in uracilemia measurements since the guidelines were implemented.

Mots clés

dihydropyrimidine dehydrogenase deficiency, false-positive reactions, fluorouracil, kidney failure, liver function tests, uracil

Référence

Ther Adv Med Oncol. 2023 01 10;15:17588359221148536